Vaccines

29 Oct 2008 Nabi Biopharmaceuticals Announces Successful Final Results of NicVAX(r) Immunogenicity Study
29 Oct 2008 Launch of a ph.III clinical trial in adults for Oralair Grasses in the US
27 Oct 2008 High-Dose Influenza Vaccine Shows Increased Immune Response Among Adults 65 Years of Age and Older
27 Oct 2008 Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two
27 Oct 2008 Nanoemulsion-Based Intranasal Influenza Vaccine Adjuvant Triggers Robust Immunity Using Significantly Less Antigen
24 Oct 2008 Vaxart Demonstrates Efficacy of Oral Avian Flu Vaccine in Preclinical Studies
23 Oct 2008 GlaxoSmithKline and AFFiRiS sign an exclusive licence and option agreement for therapeutic Alzheimer’s disease candidate vaccines
17 Oct 2008 Aeras and Crucell Announce TB Vaccine Clinical Trial in Kenya; Promising Vaccine Candidate Advances to Phase II Safety Study in South Africa
16 Oct 2008 Cell Genesys Announces Termination of VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Based on Outcome of Futility Analysis and Reports Preliminary Analysis of VITAL-2 Trial Results
15 Oct 2008 Jennerex Completes the Treatment of First Patient Cohort in Phase 1 Trial with Intravenous Delivery of JX-594 Oncolytic Virus
10 Oct 2008 Cyto Pulse, the Karolinska Institute and Uppsala University Hospital Receive Approval from the Swedish Medical Products Agency to Start a Clinical Trial Using a Xenogenic PSA DNA Vaccine
08 Oct 2008 Nventa Presents Findings on Proprietary Toll-Like Receptor 3 (TLR3) Agonist, Poly.ICR, at World Vaccine Congress
07 Oct 2008 Vical and AnGes MG Sign Letter of Intent for Pandemic Influenza Program
07 Oct 2008 Biovest Announces BiovaxID(R) Anti-Cancer Vaccine Prolongs Cancer-Free Survival by 44%
07 Oct 2008 Bavarian Nordic announces positive mature Phase II results from newly acquired prostate cancer vaccine
07 Oct 2008 Oxford Biomedica Announces FDA Agreement on Revisions for Ongoing Trovax Phase III Trist Study
02 Oct 2008 Circassia Initiates Further Phase II Clinical Study Of ToleroMune(R) Anti-Allergy Technology
01 Oct 2008 Apthera Announces Optimal Dose and Schedule of NeuVax for Phase III Clinical Trial in Breast Cancer
30 Sep 2008 VaxInnate's Second Flu Vaccine Candidate Enters Clinical Development; Results Expected in Early 2009
29 Sep 2008 MedImmune Licenses Reverse Genetics Technology to Japan's BIKEN for Use in Influenza Vaccine Development and Production
25 Sep 2008 Successful Results for Mymetics Corporation's Mucosal HIV/AIDS Vaccine Viral Challenge Significantly Exceed Expectations
23 Sep 2008 Pivotal Phase III Pollinex(R) Quattro Ragweed study meets primary efficacy endpoint
23 Sep 2008 Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins
22 Sep 2008 Opexa Announces Top-Line Results from Phase IIb Clinical Trial of Tovaxin(R) for the Treatment of Multiple Sclerosis
21 Sep 2008 Transgene's Therapeutic Vaccine TG4010: Promising Additional Clinical Data in Non Small Cell Lung Cancer Phase IIb Trial

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top